BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ABP 692 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ABP 692\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06700343-7468@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270419
DTEND;VALUE=DATE:20270420
SUMMARY:ABP 692: Phase 3 readout est. (NCT06700343)
DESCRIPTION:ABP 692\, phase 3\, Multiple Sclerosis.\nStudy: Comparison Betw
 een ABP 692 and Ocrevus® (Ocrelizumab)\nEstimated primary completion: 19 
 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/abp-692#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06700
 343
URL:https://assetmemo.bio/drug/abp-692#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
